Ligand Pharmaceuticals | LGND - Pre Tax Profit


Ligand Pharmaceuticals reported $-24.26M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Agenus USD 39.21M 49.82M Mar/2026
Amgen USD 2.08B 570M Mar/2026
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD -178.9M 41.34M Jun/2026
Baxter International USD 362M 368M Jun/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Enviri Corporation USD 233.18M 21.88M Mar/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Glaxosmithkline GBP 2.14B 312M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -11.37M 150.72M Jun/2026
Intrexon USD -60.48M 27.09M Jun/2024
Ionis Pharmaceuticals USD -114M 21M Jun/2026
Karyopharm Therapeutics USD -22.39M 17.51M Mar/2026
Ligand Pharmaceuticals USD -24.26M 81.04M Mar/2026
MacroGenics USD -36.77M 21.84M Mar/2026
Merck USD -3.53B 6.95B Mar/2026
Pacira USD 5M 4.43M Mar/2026
Pfizer USD -653M 5.84B Jun/2026
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Veracyte USD 26.52M 3.45M Jun/2026